AMMAN, Jordan, October 2, 2017 /PRNewswire/ --
Tabuk Pharmaceutical Manufacturing Company ("Tabuk"), one of the leading pharmaceutical companies in the Middle East and North Africa (MENA) region, has entered into an agreement with Selectchemie, under which Selectchemie granted Tabuk a license to register, market and sell Caspofungin Injection (systemic antifungal agent) in Saudi Arabia, the Gulf Countries, North Africa, and the rest of Middle East.
Selectchemie is one of the leading European companies, headquartered in Zurich serving the pharmaceutical and human nutrition industries since 1969 as a premier supplier of high quality ingredients.
Dr. Rana Azzam, Senior VP of Business Development said "We are excited about this major partnership collaboration with Selectchemie. Caspofungin Injection is a hard to develop and lifesaving product. This partnership will provide an opportunity for both companies to leverage their combined strength."
Selectchemie side commented "Dr. Peter Kaufmann, CEO of Selectchemie, is proud to have gained Tabuk Pharmaceutical Manufacturing Company as a licensing and marketing partner for Caspofungin in the MENA Region. With this highest quality product, manufactured in Europe, Selectchemie looks forward to a long-term partnership with Tabuk to the benefit of both companies and end-users."
SOURCE Tabuk Pharmaceuticals